FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that the company will be making presentations at upcoming drug development and investor conferences, highlighting the company’s biotechnology innovation and drug development for Alzheimer’s and neurodegenerative diseases.
Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon will present a keynote lecture, entitled “Treatment of Alzheimer’s Disease and other Neurodegenerative Disorders by Inhibition of Protein Misfolding & Aggregation,” at the 5th Drug Discovery Innovation Programme at the Embassy Suites at Logan Airport in Boston on Thursday, May 24, 2018 at 10:05 a.m. Eastern time.
Dr. Tolar will also make a presentation of Alzheon’s corporate overview at the annual JMP Securities Life Sciences Conference at the St. Regis in New York, NY, on Wednesday, June 20, 2018 at 12:00 p.m. Eastern time.
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a Precision Medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.